CHTF
6.8.2024 03:01:29 CEST | Business Wire | Press release
The 26th China Hi-tech Fair (CHTF2024) will take place on November 14-16, 2024 in Shenzhen China. This year’s fair promises to be a groundbreaking event, covering approximately 400,000m2 and attracting over 5,000 renowned enterprises and international organizations from more than 100 countries and regions. CHTF2024 will feature multiple exhibition zones covering AI and robotics, clean energy, high-end medical devices, China’s leading heavy equipment, top tech industry chains, etc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240802870555/en/
Global Buyer Invitation Programme of the 26th China Hi-tech Fair (CHTF2024) (Graphic: Business Wire)
China has solidified its position as a global technology powerhouse, with significant advancements in AI, big data, 5G, and clean energy. CHTF serves as a vital platform for debuting innovations and facilitating exchanges. In 2024, the ultimate platform invites global powerful exhibitors to win business for innovation in China’s huge tech market.
To ensure the maximum value for exhibitors, buyers, and visitors, CHTF has launched a comprehensive Global Buyer Invitation Programme, which will invite nearly 500 international buyer delegations from Europe, America, Southeast Asia, the Middle East, and other regions. The anticipated 500,000 professional visitors will create an unparalleled opportunity for business growth and networking.
Key Highlights of The Programme:
- International and Domestic Buyer Delegations: The event collaborates with prestigious buyer delegations formed by state-owned enterprises, industry leaders, and international corporations, including PetroChina (CNPC), China National Offshore Oil Corporation (CNOOC), CIPR-The conference “Digitalization of Industrial Russia”, Australian Trade & Investment Commission, etc.
- Tailored Matchmaking: Customized procurement matchmaking events and industry-specific conferences will be held to cater to the precise needs of domestic and international buyers.
- Extensive Buyer Outreach: The organizer will collect the specific procurement requirements of high-quality buyers in advance and meticulously select qualified exhibitors to ensure that the matchmaking process is precise and effective.
- Exclusive Buyer Benefits: The registered purchasers can enjoy a range of perks, including VIP privileges, streamlined entry, pre-arranged meetings with exhibitors, complimentary gifts and meals, transportation, and hotel accommodations, and additionally, a chance of lucky draw for signing contracts on-site. (Buyer benefits are subject to change without notice. Please consult the organizer for details.)
With unwavering Shenzhen government backing, extensive industry support, and proven track records of success, CHTF2024 is poised to be the premier destination to explore cutting-edge technologies, foster business collaborations, and contribute to the future of global industries.
Exhibitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/exhibit-apply.html?EID=E0000000413&target=4&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Visitor registration: https://c.zhenweiexpo.com/web-reg-server/pc/vistor-register.html?EID=E0000000413&target=1&orgnum=1164&pid=1028&version=2&cid=&ctid=1#/index
Follow us on Facebook/LinkedIn/X for updates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240802870555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 12:27:00 CET | Press release
EMA has validated two marketing authorization applications from Daiichi Sankyo in the EU for single-pill triple-combinations of established lipid-lowering agents: bempedoic acid, ezetimibe, and either atorvastatin or rosuvastatin If approved, the proposed therapies could be the first oral single-pill triple-combinations for lipid-lowering in the EU, aiming to simplify treatment for patients requiring multiple lipid-lowering agents The submissions reflect the commitment of Daiichi Sankyo to addressing unmet needs in cardiovascular disease The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinu
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 11:45:00 CET | Press release
Built with Google Cloud and Gemini for business, NIQ and Google commit to transforming AI-driven product discovery, availability, and measurement Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable,
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 11:43:00 CET | Press release
Expanded intraday and options trading capability, combined with lower options and equities commissions across the Netherlands and the EEA TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most ac
Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 11:01:00 CET | Press release
HIGHLIGHTS:Paolo Paoletti, M.D., joins Chiesi's Board of Directors as its fourth independent member, effective as of today.An internationally recognized pharmaceutical leader, he brings more than 30 years of experience spanning R&D, biotechnology innovation and global healthcare leadership.His appointment further strengthens the Board's scientific and strategic expertise as Chiesi advances its commitment to delivering innovative solutions for patients. Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of
Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 10:30:00 CET | Press release
Madrid-based appointment will focus on expanding the company’s presence across Southern Europe and developing opportunities in new markets Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expandin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom